{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:36:43Z","timestamp":1790289403009,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.metabol.2019.04.008","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T10:02:02Z","timestamp":1554976922000},"page":"92-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence"],"prefix":"10.1016","volume":"96","author":[{"given":"Niki","family":"Katsiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hahalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tentolouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippos","family":"Triposkiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Tsimihodimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri P.","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.metabol.2019.04.008_bb0005","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jcjd.2017.08.241","article-title":"The role of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes","volume":"41","author":"Steen","year":"2017","journal-title":"Can J Diabetes"},{"issue":"10","key":"10.1016\/j.metabol.2019.04.008_bb0010","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.metabol.2014.06.018","article-title":"The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors","volume":"63","author":"Wilding","year":"2014","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.metabol.2019.04.008_bb0015","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1080\/03007995.2016.1201465","article-title":"Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions","volume":"32","author":"Katsiki","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.metabol.2019.04.008_bb0020","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1517\/13543784.2011.539558","article-title":"Dapagliflozin: more than just another oral glucose-lowering agent?","volume":"19","author":"Katsiki","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/1570161115666171010122332","article-title":"Antidiabetic drugs as antihypertensives: new data on the horizon","volume":"16","author":"Mamakou","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.metabol.2019.04.008_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.metabol.2017.08.010","article-title":"Pharmacotherapy of type 2 diabetes: an update","volume":"78","author":"Upadhyay","year":"2018","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.26851","article-title":"Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways","volume":"234","author":"Yaribeygi","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.metabol.2019.04.008_bb0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.drudis.2018.08.005","article-title":"Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys","volume":"24","author":"Yaribeygi","year":"2019","journal-title":"Drug Discov Today"},{"issue":"10","key":"10.1016\/j.metabol.2019.04.008_bb0045","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.metabol.2019.04.008_bb0050","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2019.04.008_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.metabol.2019.04.008_bb0060","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.2174\/1381612823666170113152742","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management","volume":"23","author":"Katsiki","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.008_bb0065","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/EJE-17-0832","article-title":"Mechanisms in endocrinology: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?","volume":"178","author":"Esterline","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.008_bb0070","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.008_bb0075","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jdiacomp.2016.12.006","article-title":"Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: effects of statins and antidiabetic drugs","volume":"31","author":"Katsiki","year":"2017","journal-title":"J Diabetes Complications"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.008_bb0080","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2174\/1570161114666160909161811","article-title":"Editorial: can glucagon like peptide 1 (GLP1) agonists or sodium-glucose co-transporter 2 (SGLT2) inhibitors ameliorate non-alcoholic steatohepatitis in people with or without diabetes?","volume":"14","author":"Athyros","year":"2016","journal-title":"Curr Vasc Pharmacol"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.008_bb0085","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2174\/1570161116666171205105402","article-title":"Editorial: arterial stiffness, central haemodynamics and non-alcoholic fatty liver disease: links with cardiovascular risk and effects of drug treatment","volume":"16","author":"Katsiki","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.008_bb0090","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1570161115666170621075619","article-title":"Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome?","volume":"16","author":"Katsiki","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"issue":"8","key":"10.1016\/j.metabol.2019.04.008_bb0095","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.metabol.2015.09.017","article-title":"Non-alcoholic fatty liver disease and risk of cardiovascular disease","volume":"65","author":"Lonardo","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2019.04.008_bb0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.metabol.2017.04.011","article-title":"Non-alcoholic fatty liver disease: a sign of systemic disease","volume":"72","author":"Reccia","year":"2017","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.metabol.2019.04.008_bb0105","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2019.04.008_bb0110","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13098-017-0275-4","article-title":"Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus","volume":"9","author":"Yagi","year":"2017","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.008_bb0115","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s13300-017-0279-y","article-title":"Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study","volume":"8","author":"Fukuda","year":"2017","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12933-017-0516-8","article-title":"Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study","volume":"16","author":"Bouchi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.008_bb0130","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/cvr\/cvx186","article-title":"Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability","volume":"114","author":"D\u00edaz-Rodr\u00edguez","year":"2018","journal-title":"Cardiovasc Res"},{"issue":"9","key":"10.1016\/j.metabol.2019.04.008_bb0135","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00592-017-1020-z","article-title":"Epicardial adipose tissue: at the heart of the obesity complications","volume":"54","author":"Guglielmi","year":"2017","journal-title":"Acta Diabetol"},{"issue":"9","key":"10.1016\/j.metabol.2019.04.008_bb0140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4239\/wjd.v9.i9.141","article-title":"Effects of antidiabetic drugs on epicardial fat","volume":"9","author":"Xourgia","year":"2018","journal-title":"World J Diabetes"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.008_bb0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11886-018-0986-7","article-title":"The role of epicardial fat in pericardial diseases","volume":"20","author":"Lazaros","year":"2018","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.008_bb0150","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/HCO.0b013e3283605fba","article-title":"Epicardial fat and vascular risk: a narrative review","volume":"28","author":"Katsiki","year":"2013","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0155","first-page":"64","article-title":"Epicardial fat: a novel marker of subclinical atherosclerosis in clinical practice?","volume":"17","author":"Katsiki","year":"2017","journal-title":"Anatol J Cardiol"},{"issue":"5","key":"10.1016\/j.metabol.2019.04.008_bb0160","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2174\/1570161114666160722112738","article-title":"Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk?","volume":"14","author":"Katsiki","year":"2016","journal-title":"Curr Vasc Pharmacol"},{"issue":"12","key":"10.1016\/j.metabol.2019.04.008_bb0165","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/14656566.2017.1351946","article-title":"Cardiovascular disease prevention strategies for type 2 diabetes mellitus","volume":"18","author":"Katsiki","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"10.1016\/j.metabol.2019.04.008_bb0170","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00125-018-4678-z","article-title":"SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases","volume":"61","author":"Wanner","year":"2018","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"issue":"22","key":"10.1016\/j.metabol.2019.04.008_bb0180","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.008_bb0185","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.metabol.2019.04.008_bb0190","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2019.04.008_bb0195","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12984-018-0400-0","article-title":"The risk of major cardiovascular events for adults with transfemoral amputation","volume":"15","author":"Mundell","year":"2018","journal-title":"J Neuroeng Rehabil"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0200","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejvs.2013.03.024","article-title":"Short and long term mortality rates after a lower limb amputation","volume":"46","author":"Fortington","year":"2013","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.008_bb0205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5604\/01.3001.0009.8980","article-title":"Analysis of selected factors determining quality of life in patients after lower limb amputation- a review article","volume":"89","author":"Grzebie\u0144","year":"2017","journal-title":"Pol Przegl Chir"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.008_bb0210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.avsg.2007.12.012","article-title":"Does diabetes mellitus play a role in restenosis and patency rates following lower extremity peripheral arterial revascularization? A critical overview","volume":"22","author":"Paraskevas","year":"2008","journal-title":"Ann Vasc Surg"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0215","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2337\/dc17-1551","article-title":"Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.metabol.2019.04.008_bb0220","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.008_bb0225","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","article-title":"Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.008_bb0230","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/dom.13124","article-title":"Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2019.04.008_bb0235","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.008_bb0240","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/dom.13255","article-title":"SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect?","volume":"20","author":"Khouri","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"10.1016\/j.metabol.2019.04.008_bb0245","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.118.032745","article-title":"Sodium glucose cotransporter 2 inhibitors and amputation risk: Achilles' heel or opportunity for discovery?","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2019.04.008_bb0250","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-017-0611-x","article-title":"Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?","volume":"16","author":"Tanaka","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.008_bb0255","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pds.932","article-title":"Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients","volume":"13","author":"Erkens","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"10.1016\/j.metabol.2019.04.008_bb0265","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11883-017-0680-z","article-title":"The diabetic foot as a proxy for cardiovascular events and mortality review","volume":"19","author":"Dietrich","year":"2017","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0270","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1515\/folmed-2017-0014","article-title":"Demographic and comorbidity pattern of patients with critical limb ischemia","volume":"59","author":"Ciocan","year":"2017","journal-title":"Folia Med (Plovdiv)"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.008_bb0275","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2337\/dc10-0878","article-title":"Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study","volume":"34","author":"Callaghan","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0280","doi-asserted-by":"crossref","first-page":"222","DOI":"10.18433\/jpps29831","article-title":"Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"21","author":"Li","year":"2018","journal-title":"J Pharm Pharm Sci"},{"issue":"48","key":"10.1016\/j.metabol.2019.04.008_bb0285","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005473","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"95","author":"Xiong","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.008_bb0290","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/jdi.12781","article-title":"Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance","volume":"9","author":"Hattori","year":"2018","journal-title":"J Diabetes Investig"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.008_bb0295","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/2042018815578599","article-title":"Short commentary on empagliflozin and its potential clinical impact","volume":"6","author":"Hinnen","year":"2015","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.008_bb0300","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.metabol.2019.04.008_bb0305","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/dia.2017.0134","article-title":"Effect of dapagliflozin on glycemic control, weight, and blood pressure in patients with type 2 diabetes attending a specialist endocrinology practice in Canada: a retrospective cohort analysis","volume":"19","author":"Brown","year":"2017","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.008_bb0310","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/dom.13206","article-title":"Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.008_bb0315","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00125-013-2840-1","article-title":"Diabetes, bilirubin and amputations: is there a link?","volume":"56","author":"Katsiki","year":"2013","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.008_bb0320","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/dom.12418","article-title":"Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study","volume":"17","author":"Sha","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0325","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","article-title":"Effect of canagliflozin on liver function tests in patients with type 2 diabetes","volume":"42","author":"Leiter","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2019.04.008_bb0330","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/HJH.0000000000001907","article-title":"Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril","volume":"37","author":"Ramirez","year":"2019","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.008_bb0335","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jvs.2013.03.050","article-title":"Optimal medical therapy predicts amputation-free survival in chronic critical limb ischemia","volume":"58","author":"Chung","year":"2013","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.metabol.2019.04.008_bb0340","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"8","author":"Nauck","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"10.1016\/j.metabol.2019.04.008_bb0345","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.008_bb0350","first-page":"1069","article-title":"Regional differences in the expression of nitric oxide synthase and specific receptors in the vascular tissues of control and diabetic rabbits: a pilot study","volume":"21","author":"Alnaeb","year":"2007","journal-title":"In Vivo"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.008_bb0355","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther"},{"issue":"16","key":"10.1016\/j.metabol.2019.04.008_bb0360","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1016\/S0021-9258(17)32677-7","article-title":"The high affinity Na+\/glucose cotransporter. Re-evaluation of function and distribution of expression","volume":"269","author":"Lee","year":"1994","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0370","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.metabol.2019.04.008_bb0375","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40262-015-0285-z","article-title":"Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor","volume":"54","author":"Devineni","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.008_bb0395","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41574-018-0001-9","article-title":"Does lower limb amputation concern all SGLT2 inhibitors?","volume":"14","author":"Scheen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.metabol.2019.04.008_bb0400","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","article-title":"SGLT2 inhibitors and amputations in the US FDA adverse event reporting system","volume":"5","author":"Fadini","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2019.04.008_bb0405","first-page":"46","article-title":"SGLT2 inhibitors and amputation risk: real-world data from a diabetes foot wound clinic","volume":"13","author":"Sung","year":"2018","journal-title":"J Clin Transl Endocrinol"},{"issue":"5","key":"10.1016\/j.metabol.2019.04.008_bb0410","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.diabet.2018.02.001","article-title":"Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials","volume":"44","author":"Li","year":"2018","journal-title":"Diabetes Metab"},{"issue":"14","key":"10.1016\/j.metabol.2019.04.008_bb0415","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)","volume":"137","author":"Udell","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.008_bb0420","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/dom.13115","article-title":"Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study","volume":"20","author":"Yuan","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.metabol.2019.04.008_bb0425","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.008_bb0430","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/dom.13509","volume":"21","author":"Ryan","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.metabol.2019.04.008_bb0435","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.metabol.2019.04.008_bb0440","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1210\/jc.2016-3717","article-title":"Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease","volume":"102","author":"Hsu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.008_bb0445","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.jvs.2013.06.069","article-title":"Statin use and lower extremity amputation risk in nonelderly diabetic patients","volume":"58","author":"Sohn","year":"2013","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.metabol.2019.04.008_bb0450","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.coph.2018.01.003","article-title":"Lipid-lowering treatment in peripheral artery disease","volume":"39","author":"Katsiki","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.metabol.2019.04.008_bb0455","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register-based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.metabol.2019.04.008_bb0460","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1111\/dom.13459","article-title":"Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: a propensity-matched cohort study","volume":"20","author":"Adimadhyam","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.metabol.2019.04.008_bb0465","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.008_bb0470","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4103\/2230-8210.152793","article-title":"Sodium-glucose cotransporter-2 inhibition and the insulin: glucagon ratio: unexplored dimensions","volume":"19","author":"Kalra","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.008_bb0475","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrendo.2015.51","article-title":"Islet \u03b1 cells and glucagon\u2014critical regulators of energy homeostasis","volume":"11","author":"Campbell","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2019.04.008_bb0480","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-019-4839-8","article-title":"Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS program","author":"Matthews","year":"2019","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.008_bb0485","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14656566.2017.1408792","article-title":"Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study","volume":"19","author":"Nakamura","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.metabol.2019.04.008_bb0490","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.13213","article-title":"Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicentre, randomized, double-blind, open-label extension, phase 4 study in Japan (J-STEP\/INS)","volume":"20","author":"Terauchi","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.008_bb0495","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13300-017-0358-0","article-title":"Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study","volume":"9","author":"Miller","year":"2018","journal-title":"Diabetes Ther"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049519300745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049519300745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:22:23Z","timestamp":1758428543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049519300745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":94,"alternative-id":["S0026049519300745"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2019.04.008","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2019.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}